PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-51.43%
Negative net income growth while Healthcare median is 0.00%. Seth Klarman would suspect a firm-specific problem if peers maintain profit growth.
31.39%
D&A growth of 31.39% while Healthcare median is zero at 0.00%. Walter Schloss would question intangible or new expansions driving that cost difference.
No Data
No Data available this quarter, please select a different quarter.
0.95%
SBC growth of 0.95% while Healthcare median is zero at 0.00%. Walter Schloss would question expansions or staff additions causing more equity grants.
2999.17%
Working capital of 2999.17% while Healthcare median is zero at 0.00%. Walter Schloss would check if expansions or cost inefficiencies cause that difference.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
284.36%
AP growth of 284.36% while Healthcare median is zero at 0.00%. Walter Schloss would question expansions or credit policies affecting the difference.
139.25%
Growth of 139.25% while Healthcare median is zero at 0.00%. Walter Schloss would question expansions or unusual one-time factors behind the difference.
3478.66%
Growth of 3478.66% while Healthcare median is zero at 0.00%. Walter Schloss would question expansions or one-off revaluations explaining the difference.
582.93%
CFO growth of 582.93% while Healthcare median is zero at 0.00%. Walter Schloss would see a small edge that may compound with consistent execution.
-3757.14%
CapEx declines yoy while Healthcare median is 0.00%. Seth Klarman would note a short-term FCF advantage if revenue is stable.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-3757.14%
Reduced investing yoy while Healthcare median is 0.00%. Seth Klarman sees potential advantage in near-term liquidity if revenue remains stable.
-4.55%
Debt repayment yoy declines while Healthcare median is 0.00%. Seth Klarman fears increased leverage if expansions do not yield quick returns.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.